An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Tandem Diabetes Care, Inc.
VERDICT
The label
Markup
read at $23.13
Tandem Diabetes Care, Inc. holds its Markup at $23.13.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-13
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 13 days
Price
$23.13
Valuation
N/A trailing · 131.82 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.54
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$23.13
N/A P/E · 131.82 fwd
Our fair value
$14.31
38% premium
Analyst target (avg)
$26.50
+15% to current
Target low $18.00Analyst target rangeTarget high $50.00
▲ current $23.13 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$23.13
you are here
Conservative
$14.31
-38%
Analyst avg
$26.50
+15%
Our fair value
$14.31
-38%
Analyst high
$50.00
+116%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
5.80%
Profit margin
-6.08%
Debt to equity
566.96
Analyst consensus
Buy · 20 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its debt ratio. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 50.4% of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashCash held in interest-bearing accounts and securities is 22.9% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 29.1% of assets, under the 49% limit.Pass
Revenue purityOnly 0.9% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Insulin pump maker priced for perfection
Managing diabetes already demands constant precision from users, yet Tandem's shares add another layer of optimism that the numbers struggle to support. The stock sits 14% above our fair value with a forward multiple above 150 times earnings while revenue edges up just 6% and the firm still posts a 9% loss margin alongside a deeply negative 66% return on equity. Opportunity rating sits at none.
Analyst targets cluster near 28 dollars on a buy consensus, but that optimism collides with thin growth and absent profitability. The business clears our ethical screen without issue, yet the valuation leaves little room for the execution slips common in device markets where competition and reimbursement shifts can bite quickly.
High multiples on low growth often signal a value trap rather than a bargain, especially when returns on equity remain this poor. Currency moves or slower pump adoption would only widen the gap to fair value. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in TNDM's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
TNDM trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 39.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (21 analysts) rates it buy, with a mean price target of $30. Entered 2026-08-14 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-14Markup · changed$23.13+39.3%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 39.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (21 analysts) rates it buy, with a mean price target of $30.
2026-07-18Distribution$16.60+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (21 analysts) rates it buy, with a mean price target of $30.
2026-07-03Distribution$16.60+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$16.60Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$14.77
+9.9%
·
$1,099
+9.9%
2 months
$19.18
-15.4%
·
$846
-15.4%
3 months
$20.88
-22.3%
·
$778
-22.3%
6 months
$20.97
-22.6%
·
$774
-22.6%
1 year
$22.44
-27.7%
·
$723
-27.7%
2 years
$48.50
-66.5%
·
$335
-66.5%
3 years
$24.74
-34.4%
·
$656
-34.4%
5 years
$92.16
-82.4%
·
$176
-82.4%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever TNDM does next, these words stay.
Tandem Diabetes Care, Inc. · TNDM · Markup · $23.13
Recorded 2026-08-13 · before the outcome · scored mechanically